Averchenkov DM, Bejsheeva MT, Ivakina ED, Fominykh VV, Grazhdantseva LY, Ivashchenko RA, Arzumanian NS, Brylev LV, Guekht AB. [Clinical case of levamisole-induced multifocal inflammatory leukoencephalopathy].
Zh Nevrol Psikhiatr Im S S Korsakova 2020;
119:106-114. [PMID:
31994523 DOI:
10.17116/jnevro2019119121106]
[Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Levamisole is an immunomodulatory drug which can trigger development of levamisole-induced multifocal inflammatory leukoencephalopathy (LIMIL) in patients treated for helminthic invasion, aphthous stomatitis, cancer, or cocaine users. LIMIL clinical case in patient 45 years old after single dose of levamisole (taken without any medical prescription) was described. We presented clinical history and clinical picture, MRI and laboratory data and treatment results during 1-year observation. According to similarity of LIMIL with acute disseminating encephalomyelitis or debut of multiple sclerosis and high frequency of levamisole usage in Russia (usually without medical prescription) LIMIL should be included in differential diagnosis in demyelinating disorders and treated according to current clinical recommendation.
Collapse